StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Teva Pharma (TEVA) PT Lowered to $27 at Cantor Fitzgerald
August 3, 2017 12:51 PM
Cantor Fitzgerald lowered its price target on Teva Pharma (NYSE: TEVA) to $27.00 (from $31.00) while maintaining a Neutral rating ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS Change
Analyst EPS View
Analyst PT Change
Next Articles
Teva Pharma (TEVA) Grinds Lower, Shares Down Another 9%
August 7, 2017 2:58 PM
Impax Laboratories (IPXL) Reports Settlement of Contract Litigation on Opana ER (Oxymorphone Hydrochloride) CII Extended-Release Tablets
August 7, 2017 7:59 AM
Bearish Options Bias in Mylan (MYL) Ahead on Earnings Next Week -Susquehanna
August 4, 2017 2:04 PM
Teva Pharma (TEVA) PT Lowered to $28 at Deutsche Bank
August 4, 2017 8:41 AM
Credit Suisse Downgrades Teva Pharma (TEVA) to Neutral
August 4, 2017 6:01 AM
RBC Capital Double Downgrades Teva Pharma (TEVA) to Underperform
August 4, 2017 5:54 AM
Cowen Downgrades Teva Pharma (TEVA) to Market Perform
August 4, 2017 5:51 AM
